You are here ยป News

News

December 08, 2015

Collaboration will deliver healthcare professionals and consumers enhanced value and access to leading facial and body aesthetic innovations 

FORT WORTH, Texas & PLEASANTON, California, December 8, 2015 – Galderma, a global leader in skin health, and ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing its proprietary controlled-cooling technology platform, today announced a new collaboration across the companies’ innovative aesthetic brands and offerings. Effective immediately, the creation of this nationwide collaboration between two of the fastest-growing companies in the aesthetic space will provide healthcare professionals and consumers with greater access to a robust range of technologically-advanced and scientifically-proven beauty solutions for facial rejuvenation and non-invasive fat reduction.

Galderma markets leading aesthetic brands including Dysport® (a botulinum toxin A), for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines); the newly launched Restylane® Silk, the first product specifically designed to treat the lips and lines around the mouth; Restylane® Lyft, the first and only FDA-approved filler indicated to provide fullness to the midface area (cheeks) and correct and smooth the nasolabial folds ("smile lines"); and Sculptra® Aesthetic, a long-acting dermal filler, which stimulates natural collagen production, helping to increase the elasticity of the skin and smooth out deep wrinkles and folds.

ZELTIQ brings the world’s number one non-invasive fat reduction procedure, CoolSculpting®, to the new collaboration. The breakthrough procedure safely and effectively reduces unwanted fat without surgery or downtime using a patented cooling technology. Millions of CoolSculpting treatments have been performed worldwide.

In addition, the two companies will create connections between the Galderma portfolio of aesthetic brands and ZELTIQ’s CoolSculpting procedure for healthcare professionals and consumers through their respective industry-leading loyalty programs: ASPIRE Galderma Rewards loyalty program (www.aspirerewards.com) and Crystal Rewards (www.coolsculpting.com).

“The collaboration between Galderma and ZELTIQ is extremely exciting and will provide value to my practice and patients,” said Grant Stevens, MD, FACS, a board-certified plastic surgeon in California. “For many years, I have used and trusted Galderma aesthetic brands and ZELTIQ’s CoolSculpting. I am pleased this collaboration will result in greater access to these valuable products, as well as added benefits for my practice and patients through the ASPIRE Galderma Rewards and Crystal Rewards loyalty programs.”

“Galderma’s aesthetic brands and ZELTIQ’s CoolSculpting are some of the most popular aesthetic procedures performed in my practice,” said Jody Comstock, MD, a board-certified dermatologist in Arizona. “This collaboration is great news for healthcare specialists and consumers alike and demonstrates Galderma’s and ZELTIQ’s commitment to the aesthetics market.”

“At Galderma, we are focused on advancing skin health and driving category innovation for natural looking results. Through this uniquely-designed collaboration with ZELTIQ, we are bringing together leading facial aesthetic technology and non-invasive fat reduction to better serve and provide long-term value to our healthcare specialists, as well as increase awareness among consumers,” said Kelly Huang, PhD, Vice President and General Manager, Aesthetic and Corrective Business Unit, Galderma, U.S.

“ZELTIQ has revolutionized non-invasive fat reduction, as demonstrated by both physicians and consumers embracing CoolSculpting and making it the market leader. We are thrilled to collaborate with Galderma, a company that also has strong relationships in and a deep commitment to the aesthetic category,” said Mark Foley, President and Chief Executive Officer of ZELTIQ. “Our shared goal in this collaboration is to combine innovation and technology with relationships to create an extraordinary offering for healthcare professionals and consumers.”

Galderma and ZELTIQ plan to initiate a joint educational effort, as well as market growth strategies to benefit both healthcare providers and consumers.

About Galderma
Dating back to 1961, Galderma is now present in 80 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.
Strategic brands in the U.S. include Epiduo® Gel, Oracea® Capsules, Clobex® Spray, Differin® Gel, Mirvaso® Gel, MetroGel® Gel, Soolantra® Cream, Vectical® Cream, Tri-Luma® Cream, Cetaphil®, Benzac® Acne Solutions, Excipial® Skin Solutions, Restylane®, Restylane® Silk, Restylane® Lyft, Dysport® (abobotulinumtoxinA) and Sculptra® Aesthetic. For more information, please visit www.galdermausa.com.

About ZELTIQ
ZELTIQ® is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® system, is designed to selectively reduce unwanted fat that may not respond to diet or exercise. The CoolSculpting procedure is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.
All trademarks are the property of their respective owners.

For Galderma, contact:

Virginie Naigeon
Director of Corporate Communications, Galderma U.S.
virginie.naigeon@galderma.com

Ronna Waldman
MMC
+1-212-485-6907
rwaldman@mahercomm.com

For ZELTIQ, contact:

MEDIA CONTACT:
Adrienne Kemp
Gold PR
+1-949-922-0801

INVESTOR RELATIONS:
Patrick F. Williams
ZELTIQ, Senior Vice President and CFO
+1-925-474-2500

Nick Laudico
The Ruth Group
+1-646-536-7030

Posted in: Press release

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world

Read

Video

We are committed

See all videos